Meningeal carcinomatosis (MC) occurs in 5-8% of cancer patients. In the majority of cases, MC appears in patients with advanced disease. The increase in incidence is probably caused by improved survival due to improvements in systemic therapy and an increased awareness of MC among clinicians. Diagnosis is based on CSF cytology and neuroimaging. MC is a devastating condition that is associated with a poor prognosis, with a median survival time of 4-11 weeks. The treatment is in most cases palliative and involves radiotherapy and/or chemotherapy.